Kintor Pharmaceutical's (HKG:9939) clinical observational study for its KX-826 drug combined with minoxidil for males with androgenetic alopecia in mainland China reached primary endpoints.

The drug company performed the study to improve the design of its phase 3 clinical trial, according to a Friday filing with the Hong Kong bourse.

The study involved two clinical research facilities in China and assessed hair growth and adverse events, among others, the filing said.